Jump to content

Search the Community

Showing results for tags 'nia'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Welcome Center
    • Getting Started
    • New From Neuronline!
    • Community Leaders Posts
  • Virtual Events
    • Extended Discussion
    • Event Recaps
    • Live Chats
  • Neuroscience 2024
    • Roommate Matching Forum
  • Scientific Research and Training
    • Scientific Research Discussion
    • Foundations of Rigorous Neuroscience
    • Optogenetics Training Series
    • Program Development
  • Career Discussions
    • Professional Development
    • Career Advice
    • Career Paths
    • Career Stage
  • Diversity
    • Diversity Discussion
    • International Experiences
  • Outreach and Advocacy
    • Outreach and Advocacy Discussion
    • Brain Awareness & Teaching
    • Animals in Research
  • Support
  • Latin American Training Program's Webinars
  • Latin American Training Program's Opportunities
  • Latin American Training Program's Annual Meeting
  • Latin American Training Program's General Discussion
  • Latin American Training Program's Resources
  • Latin American Training Program's SfN Global Connectome 2021
  • Latin American Training Program's Live Chats
  • SfN Chapters's Topics

Calendars

  • Community Calendar
  • NSP
  • Latin American Training Program's Events
  • SfN Chapters's Events

Product Groups

There are no results to display.


Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 1 result

  1. On May 8th, the NIA release the recommendations of 60 experts on the Path to Treatment and Prevention of Alzheimer’s disease. The recommendations are listed here http://www.nia.nih.gov/research/recommendations-nih-ad-research-summit-2015. I am very concerned about one particular recommendation from SESSION ONE: Interdisciplinary Research to Understand the Heterogeneity and Multifactorial Etiology of Disease. This recommendation states, “Accept the limitations of rodent animal models and divest from using behavioral endpoints as measures of therapeutic efficacy in favor of biochemical and physiological endpoints”. The problem is, most transgenic models of Alzheimer’s do not faithfully reflect the cognitive deficits characteristic of Alzheimer’s. The field is good at adding Aß to mice and then removing Aß from those mice, but that hasn’t translated into any clinical progress. It seems that the problem is in the model; we need to seek models that better reproduce clinical symptoms. If drugs reduce behavioral pathology in mice, then this might filter what goes to clinical trial in a more optimal way. What are your thoughts? Am I misinterpreting this?
×
×
  • Create New...